Ebola virus antibody decay-stimulation in a high proportion of survivors.

ABSTRACT: Neutralizing antibody function provides a foundation for the efficacy of vaccines and therapies^1-3. Here, using a robust in vitro Ebola virus (EBOV) pseudo-particle infection assay and a well-defined set of solid-phase assays, we describe a wide spectrum of antibody responses in a cohort of healthy survivors of the Sierra Leone EBOV outbreak of 2013-2016. Pseudo-particle virus-neutralizing antibodies correlated with total anti-EBOV reactivity and neutralizing antibodies against live EBOV. Variant EBOV glycoproteins (1995 and 2014 strains) were similarly neutralized. During longitudinal follow-up, antibody responses fluctuated in a 'decay-stimulation-decay' pattern that suggests de novo restimulation by EBOV antigens after recovery. A pharmacodynamic model of antibody reactivity

SUBMITTER: Adaken C 

PROVIDER: S-EPMC7839293 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature